Evidence map›Paper›PMID 39073588›Full record

ArticleAnnals of hematology2024

Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.

Jingjing Deng, Xiaoqi Qin, Guangyu Ma, Xuliang Shen, Jingnan Sun, Yanhong Zhao, Zhihua Zhang, Ying Sun, Guitao Jie, Liping Su and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jingjing DengDepartment of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China.
Xiaoqi QinDepartment of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
Guangyu MaDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xuliang ShenDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
Jingnan SunDepartment of Oncology, The First Hospital of Jilin University, Changchun, China.
Yanhong ZhaoDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Zhihua ZhangDepartment of Hematology, Affiliated Hospital of Chengde Medical University, Chengde, China.
Ying SunDepartment of Hematology, Chifeng Municipal Hospital, Chifeng, China.
Guitao JieDepartment of Hematology, Linyi Central Hospital, Linyi, China.
Liping SuDepartment of Hematology, Shanxi Provincial Cancer Hospital, Taiyuan, China.
Jie MaDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Weiwei TianDepartment of Hematology, Shanxi Bethune Hospital of Shanxi Medical University, Taiyuan, China.
Lin YangDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Qingming WangDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Hongming HuangDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong, China.
Mingxia ShiDepartment of Hematology, Hematology Research Center of Yunnan Province, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Yanping MaDepartment of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
Wen GaoDepartment of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China. gaowenpingping@163.com.
Wenming ChenDepartment of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China. 13910107759@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of primary plasma cell leukemia (pPCL) is poor, and the relevant prognostic factors are incompletely understood. We aimed to explore the prognostic factors and develop a validated prognostic prediction model for pPCL patients in the new era. This multicenter retrospective study was conducted across 16 hospitals in China. Cox proportional hazards regression analysis was used to develop a prediction model. The predictive performance of the model was assessed using multiple metrics. Internal validation was conducted using bootstrap resampling. A total of 102 pPCL patients were included in this study, and 57 (55.9%) were male. The 12-month, 24-month, and 36-month OS rates for pPCL patients were 75.4%, 58.3%, and 47.6%, respectively. An overall survival prognostic nomogram for pPCL patients was established by integrating independent prognostic factors, including age, B2MG, and del17p. The nomogram exhibited good performance, with a C-index of 0.720 (95% CI 0.642-0.797) and an AUC of 0.653. Bootstrap validation yielded a C-index of 0.721 (95% CI 0.629-0.787) and an AUC of 0.653 (95% CI 0.546-0.759), indicating a relatively good fit of the calibration curve. A nomogram incorporating age, B2MG grade, and del17p were developed and validated to accurately and consistently predict the prognosis of pPCL patients.

Indexed as

Leukemia, Plasma CellNomogramsAdultAgedAged, 80 and overChinaFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateNomogramPlasma cell leukemiaPrimary plasma cell leukemiaPrognostic model

Identifiers

PMID39073588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.